We have proposed to study the mechanism of action of cis 1,2-diaminocyclohexyl malonato platinum (II) [(cisDACH)PT(mal)] and related compounds in the mouse L-1210 leukemia cell line. (cisDACH)Pt(mal) is a second generation platinum compound with comparable effectiveness to cis-diammino dichloro platinum (II) [cis(NH3)2Pt(Cl)2] but with better penetration of the blood brain barrier and reduced nephrotoxicity. It has already shown promise in some clinical trials. Our laboratories have recently developed new techniques to: 1) measure intracellular metabolites of (cisDACH)Pt(mal) and related platinum compounds; 2) measure platinum-DNA monoadducts, intrastrand G-G cross-links, and intrastrand G-X-G cross-links as well as interstrand cross-links; and 3) measure an excision nuclease activity capable of removing intrastrand cross-links. These techniques have not been previously available. We plan to use these techniques to answer the following questions: 1) What are the major metabolites of (cisDACH)Pt(mal) in the cell and are there significant differences between the metabolism of platinum compounds containing malonate and chloride leaving ligands? 2) What are the proportions of interand intrastrand cross-links in L-1210 cells treated with cytotoxic levels of (cisDACH)-Pt(mal) and related platinum compounds? 3) Do intrastrand cross-links correlate with the platinum induced inhibition of DNA synthesis and cytotoxicity? 4) How are intrastrand cross-links removed from the DNA of mammalian cells? and 5) What is the mechanism of resistance of the L-1210/DDP cell line to platinum (II) compounds and why is is not resistant to platinum compounds containing the DACH carrier ligand? In view of the current interest in (cisDACH)Pt(mal) and (transDACH)Pt(mal) as possible clinical drugs, the metabolic and mechanistic studies with (cisDACH)Pt(mal) should be particularly valuable at this time. In view of the widespread use of cis(NH3)2Pt(Cl)2 in the treatment of human cancers, the experiments designed to resolve the mechanism of DNA-platinum modification and repair are important. Finally, the studies with the resistant cell line of L-1210 may well serve as a model to facilitate the understanding of resistance to platinum drugs in human tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA034082-02
Application #
3171824
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
1984-01-01
Project End
1986-12-31
Budget Start
1985-01-01
Budget End
1985-12-31
Support Year
2
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
Schools of Medicine
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Vaisman, A; Varchenko, M; Umar, A et al. (1998) The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58:3579-85
Vaisman, A; Varchenko, M; Said, I et al. (1997) Cell cycle changes associated with formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity. Cytometry 27:54-64
Delmastro, D A; Li, J; Vaisman, A et al. (1997) DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 39:245-53
Chaney, S G; Sancar, A (1996) DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 88:1346-60
Vaisman, A; Keeney, S; Nichols, A F et al. (1996) Cisplatin-induced alterations in the expression of the mRNAs for UV-damage recognition protein. Oncol Res 8:7-12
Petersen, L N; Mamenta, E L; Stevnsner, T et al. (1996) Increased gene specific repair of cisplatin induced interstrand crosslinks in cisplatin resistant cell lines, and studies on carrier ligand specificity. Carcinogenesis 17:2597-602
Vaisman, A; Chaney, S G (1995) Induction of UV-damage recognition protein by cisplatin treatment. Biochemistry 34:105-14
Mamenta, E L; Poma, E E; Kaufmann, W K et al. (1994) Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 54:3500-5
Schmidt, W; Chaney, S G (1993) Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res 53:799-805
Nichols, A F; Schmidt, W J; Chaney, S G et al. (1992) Limitations of the in vitro repair synthesis assay for probing the role of DNA repair in platinum resistance. Chem Biol Interact 81:223-31

Showing the most recent 10 out of 24 publications